Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company`s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Website: januxrx.com



Growth: Good revenue growth rate 100.0%, there is slowdown compared to average historical growth rates 133.3%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -1 080.0%. Gross margin is low, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -18.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 382.9% higher than minimum and 57.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -44.7x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $24.8 mln (1.951% of cap.)

Key Financials (Download financials)

Ticker: JANX
Share price, USD:  (+5.4%)28.25
year average price 45.34  


year start price 35.40 2024-04-04

max close price 66.97 2024-12-04

min close price 26.81 2025-04-01

current price 28.25 2025-04-03
Common stocks: 41 629 400

Dividend Yield:  0.0%
EV / Sales: 228.2x
Margin (EBITDA LTM / Revenue): -1 080.0%
Fundamental value created in LTM:
Market Cap ($m): 1 176
Net Debt ($m): -35
EV (Enterprise Value): 1 141
Price to Book: 1.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-01-08seekingalpha.com

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

2024-12-06businesswire.com

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

2024-12-04businesswire.com

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

2024-12-04fool.com

Why Janux Therapeutics Crushed the Market Today

2024-12-04zacks.com

JANX Stock Hits Record High on Prostate Cancer Study Data

2024-12-03barrons.com

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

2024-12-02businesswire.com

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

2024-11-19seekingalpha.com

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

2024-09-13zacks.com

Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?

2024-08-07zacks.com

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol JANX JANX JANX JANX JANX JANX JANX JANX JANX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-07 2024-05-08 2024-03-08 2023-11-07 2023-08-08 2023-05-09 2023-03-10 2022-11-10
acceptedDate 2024-11-06 16:23:58 2024-08-07 16:28:12 2024-05-07 20:14:07 2024-03-08 16:23:07 2023-11-07 16:19:25 2023-08-08 16:33:51 2023-05-09 16:15:41 2023-03-10 16:36:09 2022-11-10 16:24:03
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 439 000 9M 1M 2M 3M 1M 2M 3M 2M
costOfRevenue 0 506 000 532 000 531 000 500 000 471 000 0 0 0
grossProfit 439 000 8M 720 000 2M 2M 586 000 2M 3M 2M
grossProfitRatio 1 0.943 0.575 0.784 0.801 0.554 1 1 1
researchAndDevelopmentExpenses 19M 15M 14M 12M 12M 15M 16M 15M 14M
generalAndAdministrativeExpenses 18M 8M 7M 6M 6M 7M 6M 6M 6M
sellingAndMarketingExpenses 0 -506 000 -532 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 18M 7M 7M 6M 6M 7M 6M 6M 6M
otherExpenses 0 -15M 0 -7M 4M 0 3M 2M 0
operatingExpenses 36M 22M 21M 19M 18M 22M 22M 21M 20M
costAndExpenses 36M 23M 21M 19M 18M 22M 22M 21M 20M
interestIncome 8M 8M 5M 4M 4M 3M 3M 2M 1M
interestExpense 0 0 0 3M 0 0 -3M 2M 1M
depreciationAndAmortization 0 506 000 532 000 531 000 500 000 471 000 453 000 403 000 249 000
ebitda -36M -13M -20M -16M -16M -20M -20M -18M -18M
ebitdaratio -81.645 -1.497 -15.678 -6.341 -6.282 -19.184 -9.903 -6.42 -9.803
operatingIncome -36M -14M -20M -16M -16M -21M -20M -18M -18M
operatingIncomeRatio -81.645 -1.554 -16.103 -6.557 -6.282 -19.629 -9.903 -6.42 -9.94
totalOtherIncomeExpensesNet 8M 8M 5M 4M 4M 3M 3M 2M 1M
incomeBeforeTax -28M -6M -15M -12M -12M -18M -17M -16M -17M
incomeBeforeTaxRatio -63.916 -0.67 -11.789 -4.778 -4.596 -16.564 -8.525 -5.647 -9.209
incomeTaxExpense 0 0 488 724 953 000 -500 000 0 -3M -5M -3M
netIncome -28M -6M -15M -12M -12M -18M -14M -11M -14M
netIncomeRatio -63.916 -0.67 -11.789 -4.778 -4.596 -16.564 -6.926 -3.958 -7.746
eps -0.51 -0.11 -0.3 -0.25 -0.25 -0.42 -0.34 -0.27 -0.34
epsdiluted -0.51 -0.11 -0.3 -0.25 -0.25 -0.42 -0.34 -0.27 -0.34
weightedAverageShsOut 55M 54M 49M 47M 46M 42M 42M 42M 42M
weightedAverageShsOutDil 55M 54M 49M 47M 46M 42M 42M 42M 42M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol JANX JANX JANX JANX JANX JANX JANX JANX JANX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-07 2024-05-08 2024-03-08 2023-11-07 2023-08-08 2023-05-09 2023-03-10 2022-11-10
acceptedDate 2024-11-06 16:23:58 2024-08-07 16:28:12 2024-05-07 20:14:07 2024-03-08 16:23:07 2023-11-07 16:19:25 2023-08-08 16:33:51 2023-05-09 16:15:41 2023-03-10 16:36:09 2022-11-10 16:24:03
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 27M 15M 213M 19M 17M 34M 30M 51M 65M
shortTermInvestments 631M 632M 439M 325M 333M 270M 287M 276M 274M
cashAndShortTermInvestments 658M 646M 652M 344M 350M 303M 317M 327M 339M
netReceivables 0 12M 4M 2M 2M 2M 750 000 0 500 000
inventory 0 1 0 -2M -2M -2M 0 0 0
otherCurrentAssets 8M 4M 2M 5M 5M 6M 4M 5M 5M
totalCurrentAssets 666M 662M 659M 349M 355M 309M 321M 332M 344M
propertyPlantEquipmentNet 25M 26M 27M 28M 29M 29M 29M 29M 29M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 816 000 816 000 816 000 816 000 816 000 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 4M 3M 3M 3M 2M 2M 2M 2M 2M
totalNonCurrentAssets 29M 29M 30M 31M 32M 32M 32M 32M 31M
otherAssets 0 0 1 0 0 0 0 0 0
totalAssets 695M 691M 689M 380M 387M 342M 353M 364M 376M
accountPayables 2M 1M 2M 2M 3M 2M 2M 2M 3M
shortTermDebt 2M 3M 2M 2M 1M 1M 1M 763 000 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 94 000 972 000 2M 4M 5M 5M 5M 6M
otherCurrentLiabilities 13M 7M 6M 7M 7M 9M 8M 8M 8M
totalCurrentLiabilities 17M 12M 11M 13M 14M 18M 16M 17M 16M
longTermDebt 22M 22M 23M 23M 23M 24M 24M 25M 24M
deferredRevenueNonCurrent 0 0 0 0 0 307 000 1M 2M 4M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 -1 0 0 0 0 0 19M
totalNonCurrentLiabilities 22M 22M 23M 23M 23M 24M 26M 27M 28M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 22M 24M 23M 25M 25M 25M 26M 25M 24M
totalLiabilities 39M 34M 33M 36M 38M 42M 42M 43M 44M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 52 000 52 000 51 000 46 000 46 000 42 000 42 000 42 000 42 000
retainedEarnings -218M -189M -184M -169M -157M -145M -128M -110M -94M
accumulatedOtherComprehensiveIncomeLoss 8M -2M -524 000 665 000 -1M -1M -739 000 -2M -2M
othertotalStockholdersEquity 866M 849M 840M 512M 507M 446M 440M 433M 428M
totalStockholdersEquity 656M 658M 656M 344M 349M 299M 311M 321M 332M
totalEquity 656M 658M 656M 344M 349M 299M 311M 321M 332M
totalLiabilitiesAndStockholdersEquity 695M 691M 689M 380M 387M 342M 353M 364M 376M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 695M 691M 689M 380M 387M 342M 353M 364M 376M
totalInvestments 631M 632M 440M 325M 333M 270M 287M 276M 274M
totalDebt 23M 24M 24M 25M 25M 25M 26M 25M 24M
netDebt -3M 9M -189M 5M 8M -8M -5M -26M -41M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol JANX JANX JANX JANX JANX JANX JANX JANX JANX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-07 2024-05-08 2024-03-08 2023-11-07 2023-08-08 2023-05-09 2023-03-10 2022-11-10
acceptedDate 2024-11-06 16:23:58 2024-08-07 16:28:12 2024-05-07 20:14:07 2024-03-08 16:23:07 2023-11-07 16:19:25 2023-08-08 16:33:51 2023-05-09 16:15:41 2023-03-10 16:36:09 2022-11-10 16:24:03
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -28M -6M -15M -12M -12M -18M -17M -16M -17M
depreciationAndAmortization 510 000 506 000 532 000 531 000 500 000 471 000 453 000 403 000 249 000
deferredIncomeTax 0 0 0 0 0 0 0 0 0
stockBasedCompensation 15M 6M 6M 4M 5M 6M 5M 4M 5M
changeInWorkingCapital 12M -7M -4M -1M -3M -2M -700 000 836 000 -795 000
accountsReceivables 8M -7M -519 000 0 0 750 000 -750 000 500 000 -500 000
inventory 0 0 0 750 000 0 -750 000 0 0 0
accountsPayables 1M -694 000 -456 000 327 000 228 000 -171 000 -107 000 223 000 -634 000
otherWorkingCapital 3M 323 000 -3M -1M -3M -2M 157 000 113 000 339 000
otherNonCashItems -2M 11M 6M -2M -2M -2M -2M -1M -768 000
netCashProvidedByOperatingActivities -2M -10M -15M -10M -12M -15M -14M -12M -13M
investmentsInPropertyPlantAndEquipment -25 000 -95 000 -197 000 -515 000 -470 000 -580 000 -285 000 -2M -3M
acquisitionsNet 0 0 0 -12M 61M -18M 0 0 0
purchasesOfInvestments -32M -236M -179M -33M -136M -77M -72M -86M -94M
salesMaturitiesOfInvestments 45M 45M 65M 45M 75M 95M 63M 87M 117M
otherInvestingActivites 0 -191M -114M 12M -61M 18M 0 0 0
netCashUsedForInvestingActivites 13M -191M -114M 11M -61M 18M -9M -2M 20M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -5M -455 000 322M 831 000 57M 528 000 2M 500 000 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M 3M 322M 831 000 57M 0 0 -309 000 0
netCashUsedProvidedByFinancingActivities 2M 3M 322M 831 000 57M 528 000 2M 191 000 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash 13M -198M 194M 2M -17M 3M -21M -13M 6M
cashAtEndOfPeriod 28M 15M 213M 20M 18M 35M 31M 52M 66M
cashAtBeginningOfPeriod 15M 213M 19M 18M 35M 31M 52M 66M 59M
operatingCashFlow -2M -10M -15M -10M -12M -15M -14M -12M -13M
capitalExpenditure -25 000 -95 000 -197 000 -515 000 -470 000 -580 000 -285 000 -2M -3M
freeCashFlow -2M -10M -15M -10M -12M -16M -14M -14M -16M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-06 21:01 ET
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
2024-08-07 20:01 ET
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
2024-07-22 20:01 ET
Janux Therapeutics Announces Updates to Board of Directors
2024-05-07 20:01 ET
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
2024-03-08 21:01 ET
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
2024-02-29 06:22 ET
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
2024-02-29 06:22 ET
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
2024-02-27 22:00 ET
Janux Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-26 21:05 ET
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
2024-02-20 13:00 ET
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
2024-01-08 14:00 ET
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
2023-11-07 21:01 ET
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
2023-08-08 20:01 ET
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
2023-07-17 12:45 ET
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2023-07-17 12:00 ET
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
2023-06-05 20:35 ET
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
2023-05-09 20:01 ET
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
2023-04-24 20:01 ET
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
2023-04-20 20:01 ET
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
2023-03-10 21:01 ET
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
2023-02-14 17:00 ET
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
2022-12-27 14:00 ET
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
2022-11-22 11:00 ET
Janux Therapeutics to Present at Upcoming Investor Conferences in November
2022-11-10 21:01 ET
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
2022-10-12 13:00 ET
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
2022-09-23 10:00 ET
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
2022-09-22 10:00 ET
Janux Therapeutics Appoints Winston Kung to Board of Directors
2022-08-31 13:00 ET
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
2022-08-09 20:01 ET
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
2022-06-02 12:00 ET
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
2022-05-31 12:00 ET
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
2022-05-10 20:01 ET
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
2022-04-26 12:30 ET
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
2022-03-18 20:01 ET
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-01 13:01 ET
Janux Therapeutics to Present at Upcoming March Investor Conferences
2022-03-01 13:00 ET
Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer
2022-01-05 21:01 ET
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
2021-11-09 21:01 ET
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
2021-11-08 13:00 ET
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
2021-09-09 20:01 ET
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
2021-09-07 20:01 ET
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
2021-08-10 20:01 ET
Janux Therapeutics Reports Second Quarter 2021 Financial Results
2021-07-19 12:00 ET
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
2021-06-15 20:01 ET
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEC forms

Show financial reports only

SEC form 10
2025-02-27 00:00 ET
Janux Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Janux Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Janux Therapeutics, Inc. published news for 2024 q4
SEC form 10
2024-11-06 16:23 ET
Janux Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-06 16:07 ET
Janux Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-06 16:07 ET
Janux Therapeutics, Inc. published news for 2024 q3
SEC form 10
2024-08-07 16:28 ET
Janux Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-07 16:20 ET
Janux Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-07 16:20 ET
Janux Therapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Janux Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Janux Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-05-07 20:14 ET
Janux Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-07 20:05 ET
Janux Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-05-07 20:05 ET
Janux Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-08 16:23 ET
Janux Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-08 16:11 ET
Janux Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-08 16:11 ET
Janux Therapeutics, Inc. published news for 2023 q4
SEC form 10
2024-03-08 00:00 ET
Janux Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-07 16:19 ET
Janux Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-07 16:07 ET
Janux Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Janux Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-08 16:33 ET
Janux Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-08 16:17 ET
Janux Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Janux Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Janux Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-18 16:16 ET
Janux Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-17 08:06 ET
Janux Therapeutics, Inc. published news for 2023 q2
SEC form 8
2023-07-17 00:00 ET
Janux Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-23 16:36 ET
Janux Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-20 17:17 ET
Janux Therapeutics, Inc. published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Janux Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Janux Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:48 ET
Janux Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-03-31 17:03 ET
Janux Therapeutics, Inc. published news for 2022 q4
SEC form 10
2023-03-10 16:36 ET
Janux Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-10 16:15 ET
Janux Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-10 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-10 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q4
SEC form 10
2022-11-10 16:24 ET
Janux Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-10 16:13 ET
Janux Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-09-22 16:46 ET
Janux Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-09 16:18 ET
Janux Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-09 16:14 ET
Janux Therapeutics, Inc. published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-06-14 19:34 ET
Janux Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 16:17 ET
Janux Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-10 16:10 ET
Janux Therapeutics, Inc. published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Janux Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-02 08:02 ET
Janux Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-29 16:47 ET
Janux Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-18 16:40 ET
Janux Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-18 16:14 ET
Janux Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-18 00:00 ET
Janux Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-18 00:00 ET
Janux Therapeutics, Inc. published news for 2021 q4
SEC form 10
2021-11-09 16:08 ET
Janux Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-09 16:03 ET
Janux Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Janux Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Janux Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-01 16:59 ET
Janux Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-09-09 17:01 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-27 16:30 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-10 16:26 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-10 16:06 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 8
2021-08-10 00:00 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-16 16:30 ET
Janux Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-15 16:10 ET
Janux Therapeutics, Inc. published news for 2021 q1